Clinical Trials Browser

Phase 1 × INDUSTRY × nazartinib × Clear all

EGFR-mutant Non-small Cell Lung Cancer

NCT03114319 2025-08-28

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

Phase 1 Terminated

227 enrolled

DermatologicGastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Melanoma, Noonan Syndrome

NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)

Phase 1 Completed

283 enrolled

BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Clinical Trials

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

A Study of PDR001 in Combination With CJM112, EGF816, Ilaris® (Canakinumab) or Mekinist® (Trametinib)